Loading Events

Arrowhead Pharmaceuticals 2024 Summer Series of R&D Webinars Part III: Pulmonary Programs – ARO-RAGE, ARO-MMP7, ARO-MUC5AC

AHA
DATE: July 16, 2024
TIME: 2:00 PM EDT
LOCATION: Virtual

About The Event

Join Arrowhead Pharmaceuticals for Part III of its 2024 Summer Series of R&D Webinars, featuring Matthias A. Salathe, MD (University of Kansas Medical Center). Arrowhead management will provide updates on its key pulmonary programs in Phase 1/2 development:

  • ARO-RAGE, designed to reduce production of the Receptor for Advanced Glycation End products (RAGE) as a potential treatment for various muco-obstructive and inflammatory pulmonary diseases.
  • ARO-MMP7, designed to the reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF).
  • ARO-MUC5AC, designed to reduce production of mucin 5AC (MUC5AC) as a potential treatment for various muco-obstructive and inflammatory pulmonary diseases.

A live question and answer session will follow the formal presentation.